Top 20 Drugs Heading for the Patent Cliff, 2026-2029
The idea of a “patent cliff” wave of exclusivity expirations shaking up the biopharma industry isn’t new: GEN first mentions the term in 2010 and again a year later when…
The idea of a “patent cliff” wave of exclusivity expirations shaking up the biopharma industry isn’t new: GEN first mentions the term in 2010 and again a year later when…
A July report by a team of Jefferies analysts paints an upbeat picture for contract development and manufacturing organizations (CDMOs). Miyabi Yamakita and colleagues reported rising demand for the services…
Credit: Charles River Laboratories Ardena Acquired Catalent’s Somerset, NJ, oral solids development and small-scale drug product manufacturing facility for an undisclosed price, in a deal completed in February. In Somerset,…